Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYH2053 Monotherapy in Primary Hypercholesterolemia or Mixed Dyslipidemia
NCT07421297Phase 3Recruiting
- Sponsor
- CSPC Zhongnuo Pharmaceutical
- Start
- Feb 2026
- Primary completion
- Dec 2027
- Modality
- Conjugated siRNA, Small Molecules, Chemically Modified siRNA
- Countries
- 1
01
Overview
A Phase 3 trial of SYH2053 in hypercholesterolemia, mixed dyslipidemia, sponsored by CSPC Zhongnuo Pharmaceutical. Started Feb 2026; status: recruiting.
02
Drugs
SYH2053
03
Conditions
hypercholesterolemiamixed dyslipidemia
Beyond the preview
Go deeper on NCT07421297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07421297.